13 results on '"Janusz, Cara B."'
Search Results
2. Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China
- Author
-
Wagner, Abram L., Lu, Yihan, Janusz, Cara B., Pan, Stephen W., Glover, Brian, Wu, Zhenke, and Prosser, Lisa A.
- Published
- 2023
- Full Text
- View/download PDF
3. Preferences for STI and cancer vaccines in the US and in China
- Author
-
Wagner, Abram L., Lu, Yihan, Janusz, Cara B., Pan, Stephen W., Glover, Brian, Wu, Zhenke, and Prosser, Lisa A.
- Subjects
Article - Abstract
This study assessed preferences for hypothetical vaccines for children in 2 large vaccine markets according to how the vaccine-preventable disease is transmitted via a discrete choice experiment.Surveys in China (N = 1350) and the United States (N = 1413) were conducted from April to May 2021. The discrete choice experiment included attributes of cost, age at vaccination, transmission mode of the vaccine-preventable disease, and whether the vaccine prevents cancer. Preference utilities were modeled in a Bayesian, multinomial logistic regression model, and respondents were grouped by vaccine preference classification through a latent class analysis.Individuals favored vaccines against diseases with transmission modes other than sexual transmission (vaccine for sexually transmitted infection [STI] vs airborne disease, in the United States, odds ratio 0.71; 95% credible interval 0.64-0.78; in China, odds ratio 0.76; 95% credible interval 0.69-0.84). The latent class analysis revealed 6 classes: vaccine rejecters (19% in the United States and 8% in China), careful deciders (18% and 17%), preferring cancer vaccination (20% and 19%), preferring vaccinating children at older ages (10% and 11%), preferring vaccinating older ages, but indifferent about cancer vaccines (23% and 25%), and preferring vaccinating children at younger ages (10% and 19%). Vaccine rejection was higher with age in the United States versus more vaccine rejection among those at the age of 18 to 24 and ≥ 64 years in China.The public had strong preferences against giving their child an STI vaccine, and the class preferring a cancer vaccine was less accepting of an STI vaccine. Overall, this study points to the need for more education about how some STI vaccines could also prevent cancers.
- Published
- 2022
4. Vaccination legislation in Latin America and the Caribbean
- Author
-
Trumbo, Silas P., Janusz, Cara B., Jauregui, Barbara, McQuestion, Mike, Felix, Gabriela, Ruiz-Matus, Cuauhtémoc, Andrus, Jon K., and de Quadros, Ciro
- Published
- 2013
5. Performing Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean
- Author
-
Janusz, Cara B., Jauregui, Barbara, Sinha, Anushua, Clark, Andrew D., Bolaños, Brenda M., Resch, Stephen, Toscano, Cristiana, and Andrus, Jon K.
- Published
- 2012
- Full Text
- View/download PDF
6. HPV vaccine introduction in the Americas: a decade of progress and lessons learned.
- Author
-
De Oliveira, Lucia H., Janusz, Cara B., Da Costa, Maria Tereza, El Omeiri, Nathalie, Bloem, Paul, Lewis, Merle, and Luciani, Silvana
- Subjects
HUMAN papillomavirus vaccines ,GENITAL warts ,CERVICAL cancer ,VACCINATION coverage ,VACCINATION status ,PUBLIC health - Abstract
Human papillomavirus (HPV) is an important public health concern due to its causative role in many cancers, especially cervical cancer, and other conditions that lead to serious health consequences in both men and women. In Latin America and the Caribbean, nearly 60,000 new cases of cervical cancer and another 7,000 HPV-associated cancers are diagnosed annually. HPV vaccination combined with comprehensive cervical cancer control programmingis paving the way for eliminating cervical cancer as a major public health problem and drastically reducing other HPV-associated diseases. To date, 44 countries and territories in the Americas have introduced HPV vaccines as part of their national immunization programs and cervical cancer control strategies. Early lessons from HPV vaccine introduction suggest that transparent and credible evidence-based decision-making, information, education and communication about HPV and cervical cancer, coordination with existing cervical cancer control initiatives, and precise planning for ensuring effective uptake of the vaccine in target groups are all critical elements of success. There is an urgent need for strategies to increase HPV vaccine coverage, and as the integrated control programs evolve and other HPV-associated disease becomes important for public health, there will be a need for continued program and policy evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
- Author
-
Janusz, Cara B., Anderson, Tara C., Leidner, Andrew J., Lee, Grace M., Dooling, Kathleen, and Prosser, Lisa A.
- Published
- 2022
- Full Text
- View/download PDF
8. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries.
- Author
-
Oliveira, Lucia H de, Shioda, Kayoko, Valenzuela, Maria Tereza, Janusz, Cara B, Rearte, Analía, Sbarra, Alyssa N, Warren, Joshua L, Toscano, Cristiana M, Weinberger, Daniel M, and Team, Multinational Study for PCV Impact in Mortality Study
- Subjects
PNEUMONIA-related mortality ,CAUSES of death ,PNEUMOCOCCAL vaccines ,TIME series analysis ,CHILD mortality ,CHILDREN - Abstract
Background Pneumococcal conjugate vaccines (PCVs) are recommended for use in pediatric immunization programs worldwide. Few data are available on their effect against mortality. We present a multicountry evaluation of the population-level impact of PCVs against death due to pneumonia in children < 5 years of age. Methods We obtained national-level mortality data between 2000 and 2016 from 10 Latin American and Caribbean countries, using the standardized protocol. Time series models were used to evaluate the decline in all-cause pneumonia deaths during the postvaccination period while controlling for unrelated temporal trends using control causes of death. Results The estimated declines in pneumonia mortality following the introduction of PCVs ranged from 11% to 35% among children aged 2–59 months in 5 countries: Colombia (24% [95% credible interval {CrI}, 3%–35%]), Ecuador (25% [95% CrI, 4%–41%]), Mexico (11% [95% CrI, 3%–18%]), Nicaragua (19% [95% CrI, 0–34%]), and Peru (35% [95% CrI, 20%–47%]). In Argentina, Brazil, and the Dominican Republic, the declines were not detected in the aggregated age group but were detected in certain age strata. In Guyana and Honduras, the estimates had large uncertainty, and no declines were detected. Across the 10 countries, most of which have low to moderate incidence of pneumonia mortality, PCVs have prevented nearly 4500 all-cause pneumonia deaths in children 2–59 months since introduction. Conclusions Although the data quality was variable between countries, and the patterns varied across countries and age groups, the balance of evidence suggests that mortality due to all-cause pneumonia in children declined after PCV introduction. The impact could be greater in populations with a higher prevaccine burden of pneumonia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Severe Acute Respiratory Infection (SARI) sentinel surveillance in the country of Georgia, 2015-2017.
- Author
-
Chakhunashvili, Giorgi, Wagner, Abram L., Power, Laura E., Janusz, Cara B., Machablishvili, Ann, Karseladze, Irakli, Tarkhan-Mouravi, Olgha, Zakhashvili, Khatuna, Imnadze, Paata, Gray, Gregory C., Anderson, Benjamin, and Boulton, Matthew L.
- Subjects
SARS diagnosis ,INFLUENZA vaccines ,MYCOPLASMA pneumoniae ,EPIDEMIOLOGY - Abstract
Background: Severe Acute Respiratory Infection (SARI) causes substantial mortality and morbidity worldwide. The country of Georgia conducts sentinel surveillance to monitor SARI activity and changes in its infectious etiology. This study characterizes the epidemiology of SARI in Georgia over the 2015/16 and 2016/17 influenza seasons, compares clinical presentations by etiology, and estimates influenza vaccine effectiveness using a test-negative design. Methods: SARI cases were selected through alternate day systematic sampling between September 2015 and March 2017 at five sentinel surveillance inpatient sites. Nasopharyngeal swabs were tested for respiratory viruses and Mycoplasma pneumoniae using a multiplex diagnostic system. We present SARI case frequencies by demographic characteristics, co-morbidities, and clinical presentation, and used logistic regression to estimate influenza A vaccine effectiveness. Results: 1,624 patients with SARI were identified. More cases occurred in February (28.7%; 466/1624) than other months. Influenza was the dominant pathogen in December-February, respiratory syncytial virus in March-May, and rhinovirus in June-November. Serious clinical symptoms including breathing difficulties, ICU hospitalization, and artificial ventilation were common among influenza A and human metapneumovirus cases. For influenza A/H3, a protective association between vaccination and disease status was observed when cases with unknown vaccination status were combined with those who were unvaccinated (OR: 0.53, 95% CI: 0.30, 0.97). Conclusions: Multi-pathogen diagnostic testing through Georgia’s sentinel surveillance provides useful information on etiology, seasonality, and demographic associations. Influenza A and B were associated with more severe outcomes, although the majority of the population studied was unvaccinated. Findings from sentinel surveillance can assist in prevention planning. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Using standardized tools to improve immunization costing data for program planning: The cost of the Colombian Expanded Program on Immunization.
- Author
-
Castañeda-Orjuela, Carlos, Romero, Martin, Arce, Patricia, Resch, Stephen, Janusz, Cara B., Toscano, Cristiana M., and De la Hoz-Restrepo, Fernando
- Subjects
- *
COST estimates , *MEDICAL economics , *HEALTH programs , *IMMUNIZATION , *COST effectiveness , *VACCINATION centers , *DRUG administration - Abstract
Highlights: [•] We present a novel tool capable of estimating a country's total EPI costs. [•] The ProVac CostVac Tool is a user-friendly, spreadsheet-based tool. [•] “CostVac” is unique because it captures EPI costs at different administrative levels. [•] We describe the use of the tool in a pilot exercise on EPI costing in Colombia. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
- Author
-
Clark, Andrew, Jauregui, Barbara, Griffiths, Ulla, Janusz, Cara B., Bolaños-Sierra, Brenda, Hajjeh, Rana, Andrus, Jon K., and Sanderson, Colin
- Subjects
- *
DECISION making in clinical medicine , *COST effectiveness , *DECISION support systems , *HAEMOPHILUS influenzae , *PNEUMOCOCCAL pneumonia , *ROTAVIRUS diseases , *VACCINATION of children - Abstract
Highlights: [•] We describe the TRIVAC model for evaluating the cost-effectiveness of 3 childhood vaccines. [•] We examine the key drivers of the TRIVAC decision support model. [•] Cost-effectiveness ratios were most sensitive to changes in relative coverage and the herd effect multiplier. [•] Identifying the key drivers helps to prioritise influential parameters for data collection. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case-control study.
- Author
-
Kahn R, Janusz CB, Castro MC, da Rocha Matos A, Domingues C, Ponmattam J, Rey-Benito G, Toscano CM, and Helena de Oliveira L
- Abstract
Background: As of September 2022, nearly 1.3 billion doses of COVID-19 vaccine products have been administered in Latin America and the Caribbean, where 27% of global COVID-19 deaths have occurred. This study aimed to estimate the effectiveness of COVID-19 vaccines against lab-confirmed COVID-19 related hospitalizations and deaths among adults in Argentina, Brazil, Chile, and Colombia., Methods: Using a test-negative case control design, we evaluated the effectiveness of a primary vaccination series considering six COVID-19 vaccine products (Sputnik V, mRNA-1273, CoronaVac, ChAdOx1, BNT162b2, Ad26.COV2.S) against lab-confirmed COVID-19 hospitalizations and deaths among 83,708 hospitalized adults from February-December, 2021. Data from hospitalization records, COVID surveillance, and vaccination registries were used. Vaccine effectiveness was estimated using logistic regression ((1-OR) x 100)., Findings: The average age of participants was 56.7 (SD = 17.5), and 45,894 (54.8%) were male. Adjusted VE (aVE) estimates for full vaccination against hospitalization were 82% for mRNA-1273 (95% confidence interval (CI) = -30 to 98%), 76% (71%-81%) for BNT162b2, 65% (61-68%) for ChAdOx1, 57% (10-79%) for Sputnik V, 53% (50-56%) for CoronaVac, and 46% (23-62%) for Ad26.COV2.S. Estimates, particularly for CoronaVac, varied by variant. Decreasing aVE was estimated as age increased, particularly for CoronaVac and ChAdOx1. aVE estimates against death were generally higher, with 100% (CI not estimated) for mRNA-1273, 82% (69-90%) for BNT162b2, 73% (69-77%) for ChAdOx1, 65% (60-67%) for CoronaVac, 38% (-75 to 78%) for Sputnik V, 6% (-58 to 44%) for Ad26.COV2.S., Interpretation: Primary series vaccination with available COVID-19 vaccine products was effective against COVID-19 hospitalization and mortality. Effectiveness varied by product and declined with increasing age., Funding: This study was funded by the Pan-American Health Organization (PAHO, World Health Organization (WHO)). PAHO convened and led the study implementation., Competing Interests: CMT received research suppport fees to support this work. CJ and RK were hired consultant to support study design, implementation, and analysis. CD has received payment or honoraria from Merck, Sanofi, Janssen, Pfizer., (© 2023 Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries.
- Author
-
de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, and Weinberger DM
- Subjects
- Argentina, Brazil, Child, Colombia, Dominican Republic, Honduras, Humans, Infant, Latin America epidemiology, Mexico, Nicaragua, Peru, Pneumococcal Vaccines, Vaccines, Conjugate, Pneumococcal Infections, Pneumonia epidemiology, Pneumonia prevention & control, Pneumonia, Pneumococcal epidemiology, Pneumonia, Pneumococcal prevention & control
- Abstract
Background: Pneumococcal conjugate vaccines (PCVs) are recommended for use in pediatric immunization programs worldwide. Few data are available on their effect against mortality. We present a multicountry evaluation of the population-level impact of PCVs against death due to pneumonia in children < 5 years of age., Methods: We obtained national-level mortality data between 2000 and 2016 from 10 Latin American and Caribbean countries, using the standardized protocol. Time series models were used to evaluate the decline in all-cause pneumonia deaths during the postvaccination period while controlling for unrelated temporal trends using control causes of death., Results: The estimated declines in pneumonia mortality following the introduction of PCVs ranged from 11% to 35% among children aged 2-59 months in 5 countries: Colombia (24% [95% credible interval {CrI}, 3%-35%]), Ecuador (25% [95% CrI, 4%-41%]), Mexico (11% [95% CrI, 3%-18%]), Nicaragua (19% [95% CrI, 0-34%]), and Peru (35% [95% CrI, 20%-47%]). In Argentina, Brazil, and the Dominican Republic, the declines were not detected in the aggregated age group but were detected in certain age strata. In Guyana and Honduras, the estimates had large uncertainty, and no declines were detected. Across the 10 countries, most of which have low to moderate incidence of pneumonia mortality, PCVs have prevented nearly 4500 all-cause pneumonia deaths in children 2-59 months since introduction., Conclusions: Although the data quality was variable between countries, and the patterns varied across countries and age groups, the balance of evidence suggests that mortality due to all-cause pneumonia in children declined after PCV introduction. The impact could be greater in populations with a higher prevaccine burden of pneumonia., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.